N※N

OGRD Alliance Expands OncoVix and PLPC-DB Initiatives from the Emirates to Asia and MENA Regions

  //business-finance.news-articles.net/content/202 .. -from-the-emirates-to-asia-and-mena-regions.html
  Published in Business and Finance on Monday, October 20th 2025 at 17:57 GMT by Finbold | Finance in Bold
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

259x194/10854 Bytes

149x101/2609 Bytes

301x167/8167 Bytes

OGRD Alliance Expands Oncovix and PLPC DB Initiatives from the Emirates to Asia and MENA Regions

The OGRD Alliance, a consortium dedicated to accelerating oncology research through collaboration between biotech innovators and data platforms, has announced a significant expansion of its Oncovix immunotherapy program and PLPC Database (PLPC DB) initiatives beyond the United Arab Emirates (UAE) into key markets across Asia and the Middle East and North Africa (MENA) region. The announcement follows successful pilot projects in Dubai and Abu Dhabi and signals a broader strategy to bring precision cancer therapies to a larger patient population.

The Strategic Partnership

The OGRD Alliance is a joint effort between Oncovix, a global oncology company focused on natural‑killer (NK) cell‑based immunotherapies, and PLPC DB, a health‑data platform that aggregates patient records, clinical trial outcomes, and real‑world evidence into a secure, AI‑ready database. Together, they aim to combine Oncovix’s biologics platform with PLPC DB’s analytical capabilities to identify biomarkers, predict treatment response, and streamline regulatory submissions.

In the UAE, the collaboration was first tested through a series of clinical trials conducted at the Dubai Health Authority (DHA) and the Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU). The trials, which focused on solid‑tumor indications such as melanoma and colorectal cancer, demonstrated a safety profile consistent with Oncovix’s global data set and provided preliminary efficacy signals that attracted the interest of regional regulators.

Expansion into Asia

OGRD Alliance’s next step is a roll‑out in Asia, beginning with Singapore, Thailand, and India. In Singapore, the consortium has partnered with the National University Hospital (NUH) and the Singapore Cancer Society to initiate a phase‑2 study of Oncovix’s NK‑Cell Activation Therapy in patients with advanced hepatocellular carcinoma. The partnership also leverages PLPC DB’s integration with the Singapore Ministry of Health’s national health database, allowing real‑time monitoring of patient outcomes and adverse events.

Thailand’s Ministry of Public Health has granted a conditional approval for a multi‑center trial in Bangkok, which will evaluate Oncovix’s therapy in patients with metastatic breast cancer. The collaboration includes Thai Cancer Institute (TCI) and the Mahidol University Faculty of Medicine. The PLPC DB platform will be localized to comply with Thai data‑protection laws, enabling secure data sharing between Thai hospitals and OGRD Alliance partners.

In India, the alliance is preparing to launch a partnership with the All‑India Institute of Medical Sciences (AIIMS) and the Indian Council of Medical Research (ICMR). The focus will be on a phase‑1/2 study of Oncovix’s therapy in pancreatic ductal adenocarcinoma, a disease with high mortality rates in the region. The partnership is also exploring the use of PLPC DB’s analytics to identify potential high‑risk populations and tailor treatment protocols.

MENA‑Wide Roll‑Out

Beyond the UAE, OGRD Alliance has secured agreements with the Saudi Food and Drug Authority (SFDA) and the Egyptian Ministry of Health to conduct joint clinical trials. The SFDA has granted a conditional approval for a phase‑2 study of Oncovix’s therapy in patients with refractory lung cancer, to be conducted at King Faisal Specialist Hospital and Research Centre in Riyadh. The trial will leverage PLPC DB’s ability to aggregate data across multiple centers, providing robust safety and efficacy data for regulatory submission.

In Egypt, the Egyptian National Cancer Institute (ENCI) has entered into a memorandum of understanding with the OGRD Alliance to pilot a phase‑1 study of Oncovix’s therapy in patients with glioblastoma multiforme. The partnership will also use PLPC DB to monitor long‑term outcomes and support pharmacovigilance activities.

The alliance has also reached out to Morocco, Jordan, and Bahrain, aiming to establish clinical research centers that can serve as hubs for oncology trials in the MENA region. Each partnership is designed to ensure compliance with local regulatory requirements, including data‑privacy standards and informed‑consent procedures.

The Role of PLPC DB

PLPC DB’s contribution to the expansion is pivotal. The platform aggregates electronic health records, laboratory results, imaging data, and patient‑reported outcomes from partner hospitals across the regions. Its machine‑learning algorithms identify patterns that correlate with therapeutic response, enabling Oncovix to refine patient selection criteria and dosing regimens.

According to a statement from PLPC DB’s CEO, “By integrating our database with the OGRD Alliance’s clinical initiatives, we can accelerate the discovery of predictive biomarkers and streamline the regulatory review process. Our focus on data interoperability ensures that patient information remains secure while facilitating meaningful collaboration among stakeholders.”

PLPC DB’s architecture also supports real‑world evidence collection, allowing OGRD Alliance to generate post‑marketing surveillance data once the therapy is approved. This data can be used to inform health‑technology assessments, reimbursement negotiations, and the development of personalized treatment protocols.

Regulatory Landscape and Future Outlook

The OGRD Alliance’s expansion aligns with the regulatory push in many Asian and MENA markets to adopt advanced immunotherapies and real‑world data approaches. In the UAE, the Dubai Health Authority’s recent policy on “Digital Health Integration” has created an enabling environment for partnerships such as this. Meanwhile, the SFDA’s “Accelerated Approval Pathway” for innovative oncology products provides a streamlined route for Oncovix’s therapy, provided the data from PLPC DB meets the evidentiary standards.

The alliance’s roadmap includes an objective to achieve market approval for Oncovix’s therapy in at least three Asian markets and two MENA countries by 2026. Simultaneously, PLPC DB aims to expand its database to include data from 20 additional hospitals across the region, enhancing its predictive analytics capabilities.

Conclusion

The OGRD Alliance’s expansion of Oncovix and PLPC DB initiatives from the Emirates into Asia and MENA represents a concerted effort to deliver cutting‑edge immunotherapy to patients in diverse healthcare ecosystems. By marrying a biologically advanced NK‑cell therapy with a sophisticated data platform, the alliance is poised to transform oncology research, accelerate regulatory approvals, and ultimately improve outcomes for cancer patients across a broad geographic spectrum.